Watch now Icon WATCH NOW: ALPROLIX data in real-world settings

ALPROLIX® offers hemostatic control for both major and minor surgeries1

Perioperative efficacy with ALPROLIX

  • Thirty-five major surgical procedures were performed in 22 subjects (age range: 10-63 years) in the adult and adolescent study and in the extension study1
    • There were an additional 62 minor surgical procedures in 37 subjects in the adult and adolescent study, the pediatric study, and the extension study. Hemostatic response was assessed for 38 minor surgeries; 36 minor surgeries were rated as excellent or good and 2 as fair1

In 100% of assessed major surgeries, hemostatic response with ALPROLIX was rated as excellent or good1

80% (28 of 35) of the major surgeries required a single perioperative dose to maintain hemostasis during surgery1

  • The median average dose per injection to maintain hemostasis during surgery was 94.7 IU/kg (range: 49 to 152). Perioperative factor IX replacement with ALPROLIX was by bolus infusion only. The safety of continuous infusion was not evaluated1
  • Hemostasis was assessed by the investigator after surgery1

Summary of Hemostatic Response for Major Surgery1

Major Surgery Number of
Procedures
(Number of
Subjects)*
Response
Excellent Good
Ablation of Liver
Lesion
1(1) 1
Arthroscopy 2(2) 2
Closure of Rectal
Fistula
1(1) 1
Craniotomy 1(1) 1
Dental Abscess 1(1) 1
Finger
Amputation or
Partial
Amputation
2(1) 2
Hip Replacement
or Repair
2(2) 1 1
Install or Removal
of External
Ilizarov Fixation
2(1) 2
Liver Transplant 1(1) 1
Liver Resection 1(1) 1
Orchiectomy 1(1) 1
Percutaneous-
Ablation of
Hepatic
Carcinoma
1(1) 1
Patellar
Resurfacing
1(1) 1
Pilonidal Cyst 1(1) 1
Pin Release 1(1) 1
Spinal Surgery 1(1) 1
Tendon Transfer
in Right Arm
1(1) 1
Tonsillectomy 1(1) 1
Unilateral Ankle
Fusion
2(2) 2
Unilateral Ankle
Replacement or
Revision
1(1) 1
Unilateral Knee
Replacement or
Revision
8(8) 6 2
Major Surgery Number of
Procedures
(Number of
Subjects)*
Response
Fair Poor/
None
Ablation of Liver
Lesion
1(1)
Arthroscopy 2(2)
Closure of Rectal
Fistula
1(1)
Craniotomy 1(1)
Dental Abscess 1(1)
Finger
Amputation or
Partial
Amputation
2(1)
Hip Replacement
or Repair
2(2)
Install or Removal
of External
Ilizarov Fixation
2(1)
Liver Transplant 1(1)
Liver Resection 1(1)
Orchiectomy 1(1)
Percutaneous-
Ablation of
Hepatic
Carcinoma
1(1)
Patellar
Resurfacing
1(1)
Pilonidal Cyst 1(1)
Pin Release 1(1)
Spinal Surgery 1(1)
Tendon Transfer
in Right Arm
1(1)
Tonsillectomy 1(1)
Unilateral Ankle
Fusion
2(2)
Unilateral Ankle
Replacement or
Revision
1(1)
Unilateral Knee
Replacement or
Revision
8(8)

*Eight subjects had more than one major surgery.1

Two surgeries were not assessed for response.1



IMPORTANT SAFETY INFORMATION AND INDICATION

IMPORTANT SAFETY INFORMATION

CONTRAINDICATIONS:

  • ALPROLIX is contraindicated in patients who have a known history of hypersensitivity reactions, including anaphylaxis, to the product or its excipients.

WARNINGS AND PRECAUTIONS:

  • Allergic-type hypersensitivity reactions, including anaphylaxis, are possible with factor replacement therapies, and have been reported with ALPROLIX. Discontinue use of ALPROLIX if hypersensitivity symptoms occur, and initiate appropriate treatment.
  • Formation of neutralizing antibodies (inhibitors) to Factor IX has been reported following administration of ALPROLIX. Patients using ALPROLIX should be monitored for the development of Factor IX inhibitors. Clotting assays (e.g., one-stage) may be used to confirm that adequate Factor IX levels have been achieved and maintained.
  • The use of Factor IX products has been associated with the development of thromboembolic complications.
  • Nephrotic syndrome has been reported following attempted immune tolerance induction in hemophilia B patients with Factor IX inhibitors and a history of allergic reactions to Factor IX. The safety and efficacy of using ALPROLIX for immune tolerance induction have not been established.

ADVERSE REACTIONS:

  • The most common adverse reactions (incidence ≥1%) in previously untreated patients were injection site erythema, hypersensitivity, and Factor IX inhibition. The most common adverse reactions (incidence ≥1%) in previously treated patients were headache, oral paresthesia, and obstructive uropathy.

INDICATION:

ALPROLIX is a recombinant DNA derived, coagulation Factor IX concentrate indicated in adults and children with hemophilia B for:

  • On-demand treatment and control of bleeding episodes
  • Perioperative management of bleeding
  • Routine prophylaxis to reduce the frequency of bleeding episodes

Limitation of Use
ALPROLIX is not indicated for induction of immune tolerance in patients with hemophilia B.

Click here to learn more about Sanofi’s commitment to fighting counterfeit drugs.

Reference: 1. ALPROLIX [package insert]. Waltham, MA: Bioverativ Therapeutics Inc.